Horizon Therapeutics Plc logo

HZNP

Horizon Therapeutics Plc

$61.14

Earnings Summary

Revenue
$876.41Mn
Net Profits
$60.97Mn
Net Profit Margins
6.96%
PE Ratio
20.02

Highlights

Revenue:

Horizon Therapeutics Plc’s revenue jumped 5.27% since last year same period to $876.41Mn in the Q2 2022. On a quarterly growth basis, Horizon Therapeutics Plc has generated -1% fall in its revenue since last 3-months.

Net Profits:

Horizon Therapeutics Plc’s net profit fell -61.44% since last year same period to $60.97Mn in the Q2 2022. On a quarterly growth basis, Horizon Therapeutics Plc has generated -70.15% fall in its net profits since last 3-months.

Net Profit Margins:

Horizon Therapeutics Plc’s net profit margin fell -63.37% since last year same period to 6.96% in the Q2 2022. On a quarterly growth basis, Horizon Therapeutics Plc has generated -69.85% fall in its net profit margins since last 3-months.

PE Ratio:

Horizon Therapeutics Plc’s price-to-earnings ratio after this Q2 2022 earnings stands at 20.02.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Horizon Therapeutics Plc post its latest quarter earnings

EPS Estimate Current Quarter
1.35
EPS Estimate Current Year
1.35

Highlights

EPS Estimate Current Quarter:

Horizon Therapeutics Plc’s earning per share (EPS) estimates for the current quarter stand at 1.35 - a 18.42% jump from last quarter’s estimates.

EPS Estimate Current Year:

Horizon Therapeutics Plc’s earning per share (EPS) estimates for the current year stand at 1.35.

Key Ratios

Key ratios of the Horizon Therapeutics Plc post its Q2 2022 earnings

Earning Per Share (EPS)
1.07
Return on Assets (ROA)
0.07
Return on Equity (ROE)
0.17
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Horizon Therapeutics Plc’s earning per share (EPS) fell -33.95% since last year same period to 1.07 in the Q2 2022. This indicates that the Horizon Therapeutics Plc has generated -33.95% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Horizon Therapeutics Plc’s return on assets (ROA) stands at 0.07.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Horizon Therapeutics Plc’s return on equity (ROE) stands at 0.17.

Dividend Per Share (DPS):

Horizon Therapeutics Plc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
1.14
1.34
17.54%
2022-06-30
1.35
1.07
-20.74%

Company Information

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives.

Organisation
Horizon Therapeutics Plc
Employees
1.4K
Industry
Health Technology